Clinical Trial Update: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating Raludotatug Deruxtecan (R-DXd) in platinum-resistant, high-grade ovarian cancer, primary peritoneal cancer, or fallopian t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Raludotatug Deruxtecan (R-DXd) (Raludotatug deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Solid Cancer | Phase 2, Phase 3 | Status: RECRUITING